Acquired aplastic anemia is a rare, serious blood disorder, which is characterized by failure of the bone marrow and its inability to produce blood cells. Bone marrow is found in the center of the bones and appears to be like a spongy substance. It is responsible for the production of red blood cells along with other blood components.
Aplastic anemia has two manifestations, i.e. Acquired aplastic anemia and inherit aplastic anemia Acquired aplastic anemia is more common, and sometimes it's only temporary whereas, it is a rare disorder as compared to inherit aplastic anemia. Various causes of acquired aplastic anemia includes toxins, such as pesticides, arsenic, and benzene, radiation and chemotherapy-treatments, infectious diseases, such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV. And autoimmune disorders, such as lupus and rheumatoid arthritis. Sometimes, cancer from another part of the body can spread to the bone and cause acquired aplastic anemia.
The acquired aplastic anemia market growth is majorly attributed to the increasing prevalence of the blood disorders, rising funding, healthcare insurance coverage, and awareness programs for blood disorders.
According to the 2014 Annual Global Survey of the World Federation of Hemophilia (WFH), the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with Von Willebrand disease, and 1,123 with other blood disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years
A research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia and most dominant in male patients is 1:?5000 to 10,000. Whereas, the prevalence rate of hemophilia B is 1:?34,500 male patients.
Moreover, advancing technology in medical devices is adding fuel to the growth of the market. Furthermore, increasing prevalence of cancer also drives the market growth.
However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.
The global acquired aplastic anemia market is expected to grow at a CAGR of 7.6 % during the forecast period 2017-2023
Segmentations
The global acquired aplastic anemia market is segmented on the basis of types, by diagnosis, by treatment, and by end user.
On the basis of type, it is segmented into moderate aplastic anemia, severe aplastic anemia, and very severe aplastic anemia.
On the basis of diagnosis, it is segmented into bone marrow biopsy, X-rays, computed tomography (CT) scans, and others.
On the basis of treatment, it is segmented into bone marrow transplantation, immunosuppressive therapies, and others.
On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.
Key Players
Some of key the players in the market are Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), CSL Limited (Australia), Amgen Inc., GlaxoSmithKline plc., and Bluebird bio.
Request Customization
Get a Sample
Get a Sample
Request Customization